ArticleMolecular and cellular biochemistry2026
Matrine functions as a tumor inhibitor to influence proliferation, metastasis and glycolysis in colorectal cancer via depending on METTL14-mediated m6A methylation of MEX3A.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrine is considered as an anti-cancer drug in a variety of cancers, including colorectal cancer (CRC). Methyltransferase-like 14 (METTL14) and Mex-3 RNA binding family member A (MEX3A) were associated with CRC progression. This study focused on the mechanism of matrine with METTL14 and MEX3A in CRC. Cell viability, proliferation, apoptosis, and migration/invasion were assessed by cell counting kit-8, EdU assay, flow cytometry, and transwell assay. Glycolysis metabolism was evaluated by glucose consumption and ATP/ADP ratio using kits. RT-qPCR and Western blot were employed for expression examination. Gene interaction was analyzed via methylated RNA immunoprecipitation (MeRIP) and RIP assays. The role of matrine in vivo was explored by xenograft models in mice. CRC cell proliferation, metastasis and glycolysis were restrained by matrine. METTL14 was up-regulated in matrine-treated CRC cells. Anti-tumor effects of matrine on CRC cells were associated with upregulation of METTL14. METTL14 reduced MEX3A expression by mediating the m6A modification of MEX3A, and YTHDF1 acted as a "reader" protein to affect m6A methylation of MEX3A. METTL14 suppressed CRC cell malignant progression via inhibiting MEX3A. MEX3A overexpression recused the tumor-inhibitory regulation of matrine in CRC cells. Matrine also repressed tumor growth of CRC in vivo through downregulating MEX3A. This study revealed that matrine played a cancer-suppressive role in CRC through targeting METTL14/MEX3A network, unraveling a molecular mechanism of matrine in CRC inhibition.
Indexed as
Identifiers
41525024What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.